Results 41 to 50 of about 16,507 (152)

New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects

Терапевтический архив, 2021
Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to
Natalia A. Dragomiretskaya, Aida I. Tarzimanova, Julia S. Kucherova, Valery I. Podzolkov   +3 more
doaj   +1 more source

The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients.

Albanian Journal of Trauma and Emergency Surgery, 2022
Inappropriate activation of the mineralocorticoid receptor (MR) plays a significant role in developing hypertension, the development of cardiac pathological changes, and chronic kidney disease (CKD), where death related to cardiovascular (CV) causes is ...
Eqerem Hasani, Merita Rroji, Myftar Barbullushi   +2 more
doaj   +1 more source

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT

Российский кардиологический журнал, 2015
The review takes into consideration the novel data on heart failure treatment: application of mineralocorticoid antagonists. The pathogenetic points are highlighted that are proved by clinical trials, as epidemiological concerns. Further opportunites are
V. N. Soboleva, E. O. Taratukhin
doaj   +1 more source

Carbonyl reductase 1 amplifies glucocorticoid action in adipose tissue and impairs glucose tolerance in lean mice

Molecular Metabolism, 2021
Objective: Carbonyl reductase 1 (Cbr1), a recently discovered contributor to tissue glucocorticoid metabolism converting corticosterone to 20β-dihydrocorticosterone (20β-DHB), is upregulated in adipose tissue of obese humans and mice and may contribute ...
Rachel M.B. Bell, Elisa Villalobos, Mark Nixon, Allende Miguelez-Crespo, Lee Murphy, Angie Fawkes, Audrey Coutts, Matthew G.F. Sharp, Martha V. Koerner, Emma Allan, Onno C. Meijer, Renè Houtman, Alex Odermatt, Katharina R. Beck, Scott G. Denham, Patricia Lee, Natalie Z.M. Homer, Brian R. Walker, Ruth A. Morgan   +18 more
doaj   +1 more source

Intrarenal Hemodynamic Mechanisms of Kidney Protection by Nonsteroidal Mineralocorticoid Receptor Antagonists [PDF]

Endocrinology and Metabolism
Nonsteroidal mineralocorticoid receptor antagonists (nsMRAs), especially finerenone, have shown significant cardiorenal benefits in patients with chronic kidney disease (CKD).
Eun Sil Koh, So Young Lee, Doan Thi Thien Hao, Sungjin Chung   +3 more
doaj   +1 more source

Molecular, Cellular, and Clinical Evidence That Sodium‐Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure.
Milton Packer
doaj   +1 more source

Role of Mineralocorticoid Receptor Antagonists in Cardiovascular Disease [PDF]

Circulation Research, 2015
Aldosterone exerts its best known sodium homeostasis actions by controlling sodium excretion at the level of the distal tubules via activation of the apical epithelial sodium channel and the basolateral Na+/K+ATPase pump. Recently, this mineralocorticoid hormone has been demonstrated to act on the heart and blood vessels.
Carlos M, Ferrario, Ernesto L, Schiffrin
openaire   +2 more sources

Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease [PDF]

Clinical Journal of the American Society of Nephrology, 2020
Ten years ago, I presented an outline for a study aiming to prevent diabetic kidney disease (DKD), with early intervention in subjects with type 2 diabetes and high risk for DKD assessed by a urinary proteomic–based biomarker, at Kidney Week hoping for positive feedback.
openaire   +3 more sources

Effect of Mineralocorticoid receptor antagonism (MRA) on aldosterone-interleukin 6 axis in heart failure; second opinion. A case-control study

The Egyptian Journal of Internal Medicine
Background In cases of heart failure characterized by reduced ejection fraction (HFrEF), heightened levels of aldosterone negatively impact the progression of heart failure.
H. ElSawi, S. Zidan, A. Elborolosy
doaj   +1 more source

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection

Медицинский совет, 2018
The article presents the contemporary views of the role of aldosterone in the progression of cardiovascular and renal diseases. It addresses matters related to the efficacy and safety of mineralocorticoid receptor antagonists in patients with chronic ...
A. M. Esayan, A. N. Nimgirova
doaj   +1 more source